Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Aug 9;13(Suppl 1):26.
doi: 10.1186/s40248-018-0143-6. eCollection 2018.

Why, when and how to investigate primary ciliary dyskinesia in adult patients with bronchiectasis

Martina Contarini #  1 , Amelia Shoemark #  2 , Jessica Rademacher  3 , Simon Finch  2 , Andrea Gramegna  1 , Michele Gaffuri  4 , Luca Roncoroni  4 , Manuela Seia  5 , Felix C Ringshausen  3 , Tobias Welte  3 , Francesco Blasi  1 , Stefano Aliberti  1 , James D Chalmers  2
Affiliations
Review

Why, when and how to investigate primary ciliary dyskinesia in adult patients with bronchiectasis

Martina Contarini et al. Multidiscip Respir Med. .

Abstract

Bronchiectasis represents the final pathway of several infectious, genetic, immunologic or allergic disorders. Accurate and prompt identification of the underlying cause is a key recommendation of several international guidelines, in order to tailor treatment appropriately. Primary ciliary dyskinesia (PCD) is a genetic cause of bronchiectasis in which failure of motile cilia leads to poor mucociliary clearance. Due to poor ciliary function in other organs, individuals can suffer from chronic rhinosinusitis, otitis media and infertility. This paper explores the current literature describing why, when and how to investigate PCD in adult patients with bronchiectasis. We describe the main PCD diagnostic tests and compare the two international PCD diagnostic guidelines. The expensive multi-test diagnostic approach requiring a high level of expertise and specialist equipment, make the multifaceted PCD diagnostic pathway complex. Therefore, the risk of late or missed diagnosis is high and has clinical and research implications. Defining the number of patients with bronchiectasis due to PCD is complex. To date, few studies outlining the aetiology of adult patients with bronchiectasis conduct screening tests for PCD, but they do differ in their diagnostic approach. Comparison of these studies reveals an estimated PCD prevalence of 1-13% in adults with bronchiectasis and describe patients as younger than their counterparts with moderate impairment of lung function and higher rates of chronic infection with Pseudomonas aeruginosa. Diagnosing PCD has clinical, socioeconomic and psychological implications, which affect patients' life, including the possibility to have a specific and multidisciplinary team approach in a PCD referral centre, as well as a genetic and fertility counselling and special legal aspects in some countries. To date no specific treatments for PCD have been approved, standardized diagnostic protocols for PCD and recent diagnostic guidelines will be helpful to accurately define a population on which planning RCT studies to evaluate efficacy, safety and accuracy of PCD specific treatments.

Keywords: Adult; Aetiology; Bronchiectasis; Primary ciliary dyskinesia.

PubMed Disclaimer

Conflict of interest statement

Not applicableNot applicableThe authors declare that they have no competing interests. Prof. Francesco Blasi is Editor-in-Chief of Multidisciplinary Respiratory Medicine, whereas Profs. Tobias Welte and Stefano Aliberti are Associate editors of Multidisciplinary Respiratory Medicine. In addition, Profs. Stefano Aliberti and James D Chalmers are Guest Editors of the Supplement on Bronchiectasis.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Similar articles

  • Primary Ciliary Dyskinesia.
    Shoemark A, Harman K. Shoemark A, et al. Semin Respir Crit Care Med. 2021 Aug;42(4):537-548. doi: 10.1055/s-0041-1730919. Epub 2021 Jul 14. Semin Respir Crit Care Med. 2021. PMID: 34261178
  • Prevalence of chronic rhinosinusitis in bronchiectasis patients suspected of ciliary dyskinesia.
    McCormick JP, Weeks CG, Rivers NJ, Owen JD, Kelly DR, Rowe SM, Solomon GM, Woodworth BA, Cho DY. McCormick JP, et al. Int Forum Allergy Rhinol. 2019 Dec;9(12):1430-1435. doi: 10.1002/alr.22414. Epub 2019 Aug 20. Int Forum Allergy Rhinol. 2019. PMID: 31430425 Free PMC article.
  • Genome sequencing reveals underdiagnosis of primary ciliary dyskinesia in bronchiectasis.
    Shoemark A, Griffin H, Wheway G, Hogg C, Lucas JS; Genomics England Research Consortium; Camps C, Taylor J, Carroll M, Loebinger MR, Chalmers JD, Morris-Rosendahl D, Mitchison HM, De Soyza A; Genomics England Research Consortium:; Brown D, Ambrose JC, Arumugam P, Bevers R, Bleda M, Boardman-Pretty F, Boustred CR, Brittain H, Caulfield MJ, Chan GC, Fowler T, Giess A, Hamblin A, Henderson S, Hubbard TJP, Jackson R, Jones LJ, Kasperaviciute D, Kayikci M, Kousathanas A, Lahnstein L, Leigh SEA, Leong IUS, Lopez FJ, Maleady-Crowe F, McEntagart M, Minneci F, Moutsianas L, Mueller M, Murugaesu N, Need AC, O'Donovan P, Odhams CA, Patch C, Perez-Gil D, Pereira MB, Pullinger J, Rahim T, Rendon A, Rogers T, Savage K, Sawant K, Scott RH, Siddiq A, Sieghart A, Smith SC, Sosinsky A, Stuckey A, Tanguy M, Taylor Tavares AL, Thomas ERA, Thompson SR, Tucci A, Welland MJ, Williams E, Witkowska K, Wood SM. Shoemark A, et al. Eur Respir J. 2022 Nov 17;60(5):2200176. doi: 10.1183/13993003.00176-2022. Print 2022 Nov. Eur Respir J. 2022. PMID: 35728977
  • Primary Ciliary Dyskinesia: An Update on Clinical Aspects, Genetics, Diagnosis, and Future Treatment Strategies.
    Mirra V, Werner C, Santamaria F. Mirra V, et al. Front Pediatr. 2017 Jun 9;5:135. doi: 10.3389/fped.2017.00135. eCollection 2017. Front Pediatr. 2017. PMID: 28649564 Free PMC article. Review.
  • Primary ciliary dyskinesia: a major player in a bigger game.
    Bhatt R, Hogg C. Bhatt R, et al. Breathe (Sheff). 2020 Jun;16(2):200047. doi: 10.1183/20734735.0047-2020. Breathe (Sheff). 2020. PMID: 33304404 Free PMC article. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Pasteur MC, Bilton D, Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010;65(Suppl 1):i1–58. doi: 10.1136/thx.2010.136119. - DOI - PubMed
    1. McDonnel MJ, Aliberti S, Goeminne PC, Restrepo MI, Finch S, Pesci A, et al. Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. Lancet Respir Med. 2016;4(12):969–979. doi: 10.1016/S2213-2600(16)30320-4. - DOI - PMC - PubMed
    1. Quint JK, Millett ER, Joshi M, Navaratnam V, Thomas SL, Hurst JR, et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. Eur Respir J. 2016;47(1):186–193. doi: 10.1183/13993003.01033-2015. - DOI - PMC - PubMed
    1. Monteagudo M, Rodríguez-Blanco T, Barrecheguren M, Simonet P, Miravitlles M. Prevalence and incidence of bronchiectasis in Catalonia, Spain: a population-based study. Respir Med. 2016;121:26–31. doi: 10.1016/j.rmed.2016.10.014. - DOI - PubMed
    1. Ringshausen FC, de Roux A, Diel R, Hohmann D, Welte T, Rademacher J. Bronchiectasis in Germany: a population-based estimation of disease prevalence. Eur Respir J. 2015;46(6):1805–1807. doi: 10.1183/13993003.00954-2015. - DOI - PubMed